Health TrialsbyHealthPanel

Real-World Study on the Burden of Hidradenitis Suppurativa

ConditionHidradenitis Suppurativa (HS)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPeriPharm

About this trial

Despite the significant impact of HS on patients' quality of life (QoL) and daily functioning, there remains limited real-world evidence describing the burden of this condition in Canada. HS is an under-recognized and often misdiagnosed condition, with a substantial psychological and physical burden on patients. Understanding the real-world experiences of individuals living with HS in Canada can help identify unmet needs and inform patient-centered care approaches.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient diagnosed with HS;

Aged ≥18 years;

Able to read and understand French or English;

Willing and able to provide written informed consent.

Disqualifiers

None

Trial population

Adult patients with HS

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • No Intervention: Observational Cohort

    Other intervention

    No specific intervention is assess in this study. Observational cohort.

Treatment groups

100 Participants
are divided into 1 treatment group
Group A: Patient with HS1 intervention

Trial outcomes

Primary outcomes

1

To estimate work productivity loss in patients with HS.

Using the Work Productivity and Activity Impairment (WPAI) questionnaire. This questionnaire provides a quantitative measure of impairment over the last 7 days and includes four metrics: absenteeism (work time missed because of health issues during the past 7 days), presenteeism (impairment while working due to health issues during the past 7 days), overall work productivity loss (combination of absenteeism and presenteeism), and activity impairment.

Time frame
At recruitment

Secondary outcomes

1

To estimate the QoL of patients with HS

The Hidradenitis Suppurativa Quality of Life Questionnaire (HiSQOL) is a validated, HS-specific instrument designed to capture the multidimensional impact of HS on quality of life over the previous 7 days. It consists of 17 items that use Likert-type response options, ranging from 0 ("not at all") to 4 ("extremely"), with some items allowing respondents to indicate that an activity was not performed due either to lack of relevance or HS severity

Time frame
At recruitment
2

To estimate pain intensity in patients with HS.

Patients with HS will self-report the worst intensity of their pain over the past 7 days using an 11-point numeric rating scale (NRS). The NRS ranges from 0 ("No Pain") to 10 ("The worst imaginable Pain"). Pain was selected as a key symptom given its substantial impact on patients' daily lives and QoL. The 7-day recall period was chosen to balance recall accuracy and symptom variability, capturing recent disease activity while minimizing recall bias.

Time frame
At recruitment

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

PeriPharm

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: